Boston, MA 06/05/2014 (wallstreetpr) – Baxter International Inc. (NYSE:BAX) is a global leader in health care services. The company caters to the needs of the people through many of its subsidiaries. These subsidiaries are actively involved in developing, manufactured and marketing products that make the health of people better thus giving them a better life to live. The patients linked to this company either have hemophilia, immune disorders, infectious diseases, kidney disease, trauma, or some other chronic and acute medical conditions. BAX operates in two segments – one is Bioscience, and other is Medication Delivery. Both these segments simply aim to offer its services like medical devices, biotechnology and pharmaceutical products to patients worldwide. These products are employed in kidney dialysis centers, doctors’ offices, clinical and medical research labs and many nursing homes. Baxter International Inc. (NYSE:BAX) has its manufacturing units in nearly 27 countries and has clientage in over 100 countries.
BAX’s ADVATE (Antihemophilic Factor (Recombinant))
With a spirit to make the lives of people better and healthy, Baxter International Inc. (NYSE:BAX) launched its ADVATE (Antihemophilic Factor (Recombinant)) many years back which has now become the leading treatment of hemophilia A. This ADVATE is the first recombinant treatment which has no animal or human proteins added to it. By launching this recombinant, BAX has secured its global leadership position in hemophilia a field. ADVATE has been in the market for more than 10 years and near about 17 billion units have been distributed throughout. After such long observance, now the new approvals and the tenders support an increased access to ADVATE, which makes ADVATE world’s leading recombinant. And ultimately helps BAX to build on Global leadership in hemophilia A.
Recent Highlights From All Around
European Union regulatory approves of a new manufacturing facility in Singapore, which will produce a variety of recombinant proteins which include Baxter International Inc. (NYSE:BAX)’s ADVATE. Recently, National Blood Authority (NBA) in Australia announced a four-year-award for ADVATE. This award will provide 2,300 hemophilia patients an access to this therapy. Followed by this is UK’s multi-year award which will offer access to this treatment to nearly 5,600 people. U.S FDA also approved a new reconstitution system of ADVATE which reduces the number of steps in the reconstitution process for hemophilia a patients and their near ones.
